Clinical trialsCompany release

Pyxis Oncology aligns with FDA and EMA on Phase 3 head and neck trial design

🇺🇸 Pyxis Oncology, Inc. (PYXS) · Thu 05 Nov 2026

The company plans to start the global Headliner study of micvotabart pelidotin in mid-2027, with FDA feedback on dose selection due in the first quarter of 2027.

Pyxis Oncology said on 5 November 2026, alongside its third-quarter results, that it has reached alignment with both the US Food and Drug Administration and the European Medicines Agency on the design of a global Phase 3 trial of micvotabart pelidotin (MICVO). The study, called Headliner, will enrol patients with recurrent or metastatic head and neck squamous cell carcinoma who have received at least one prior line of therapy.

The company plans to begin the trial in mid-2027. It expects FDA feedback on dose selection, arising from its End-of-Phase 2 meeting, in the first quarter of 2027. Dose selection therefore remains an open regulatory item ahead of the planned start.

Pyxis also reported updated Phase 1 data for MICVO as a monotherapy, showing a 36% confirmed response rate and no new safety signals. The summary provided does not give patient numbers, duration of response or other detail on the dataset.

On financing, Pyxis completed a public offering in October that brought in about $110 million upfront. The company says this extends its cash runway into the first half of 2028, which would cover the planned Phase 3 start.

What it means for your team

  • Early agreement with both FDA and EMA on a single global Phase 3 design may reduce the risk of divergent regional requirements, though dose selection is still pending with the FDA.
  • The Q1 2027 FDA feedback on dose selection is the next regulatory milestone to watch before the mid-2027 trial start.
  • Safety teams in the field should note that the company reports no new safety signals in the updated Phase 1 monotherapy data; fuller data would be needed to assess this.
  • The extended cash runway into the first half of 2028 covers the planned trial start, which is relevant to assessing programme continuity.

Company's press release (SEC filing): Pyxis Oncology, Inc. ↗

Article written by VigiEye from the official source (Pyxis Oncology, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →